The nation of Zimbabwe has rejected a significant American health deal worth $367m (£272m) over five years due to the United States' insistence on confidential biological samples.
This rejection was revealed after a official document dated December was leaked, which showed President Emmerson Mnangagwa believed the agreement was "skewed".
A government representative later clarified that the United States was requesting health data for scientific study and commercial gain while refused to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged more negotiations to reach a agreement agreeable to all parties so the nation's vital HIV treatment initiative can proceed.
Wider Background
This development follows a similar situation in neighbouring Kenya, where a court halted a related health funding agreement following concerns were raised about the safety of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump stated its spending was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and accountability.
As per reports, 16 African countries have so far signed similar agreements, representing more than $18.3bn in new funding.
Details of the Declined Deal
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment through US-supported programmes," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to share its biological resources and data over an extended period, without any equivalent guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that provided information," his statement read.
"Effectively, our nation would provide the raw materials for medical research without any certainty that the final treatments would be available to our citizens if a future health crisis arise."
Sovereignty and Global Health
He also said that the American exit from the global health body and its pursuit of bilateral health agreements were upending structures already established through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing system designed to manage potential pandemics.
"This system is designed to ensure that when a country contributes its data, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We are open to continued dialogue with our US partners on how future collaboration might be designed in a way that honours the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but recommended that talks must proceed given that much of the nation's HIV programmes were funded by international support.
"In cases where technical issues exist, including those involving data governance or agreement terms, these can frequently be addressed through technical clarification and negotiated safeguards," the group commented.
The halted deal underscores the continuing debate between accepting crucial international aid and safeguarding national sovereignty in an ever more data-driven world.